에서 실시간으로 운영 중이에요! 자세히 알아보기

Inogen

INGN

시가총액 US$1.66억

6.25 USD

-0.05

0.79%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-0.79%

5일

1.3%

1개월

21.83%

3개월

-6.16%

6개월

-5.16%

연초 이후

-5.73%

1년

-26.56%

5년

-84.87%

10년

-88.91%

소개: Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

직원 수: 753

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 10%

중립 60%

부정적 30%

Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026.

Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026

Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.

Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech

Zacks Investment Research

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

Zacks Investment Research

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Zacks Investment Research

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Zacks Investment Research

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript

Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript

Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript

Inogen Q2 Earnings Call Highlights

Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.

Inogen Q2 Earnings Call Highlights

Zacks Investment Research

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

Inogen Announces Second Quarter 2026 Financial Results

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million.

Inogen Announces Second Quarter 2026 Financial Results

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.